-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Akebia Therapeutics (NASDAQ:AKBA) Earns Hold Rating From Analysts at StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Earns Hold Rating From Analysts at StockNews.com
StockNews.com initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
Separately, HC Wainwright cut their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akebia Therapeutics currently has an average rating of Hold and an average target price of $1.75.
Get Akebia Therapeutics alerts:Akebia Therapeutics Stock Performance
NASDAQ AKBA opened at $0.38 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The firm has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.85. Akebia Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.35.
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.54. The firm had revenue of $126.76 million during the quarter, compared to analysts' expectations of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. During the same quarter last year, the company earned ($0.51) earnings per share. As a group, research analysts forecast that Akebia Therapeutics will post -0.44 EPS for the current fiscal year.Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AKBA. Point72 Hong Kong Ltd bought a new position in Akebia Therapeutics during the 4th quarter valued at about $30,000. BNP Paribas Arbitrage SA increased its holdings in Akebia Therapeutics by 123.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $40,000. Finally, MetLife Investment Management LLC grew its holdings in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 54,389 shares in the last quarter. 31.56% of the stock is owned by hedge funds and other institutional investors.
About Akebia Therapeutics
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Further Reading
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
斯托克新闻网在周日上午发布的一份研究报告中对木通治疗公司(纳斯达克：AKBA-GET评级)的股票进行了报道。该经纪公司对这家生物制药公司的股票发布了持有评级。
Separately, HC Wainwright cut their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akebia Therapeutics currently has an average rating of Hold and an average target price of $1.75.
另外，在5月16日星期一的一份研究报告中，HC Wainwright将木通治疗公司的股票目标价从2.00美元下调至1.25美元。根据MarketBeat的数据，七位研究分析师对该股的评级为持有，木通治疗公司目前的平均评级为持有，平均目标价为1.75美元。
Akebia Therapeutics Stock Performance
木通治疗公司股票表现
NASDAQ AKBA opened at $0.38 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The firm has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.85. Akebia Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.35.
纳斯达克AKBA上周五开盘报0.38美元。该公司的流动比率为1.30，速动比率为1.15，债务权益比率为0.51。该公司的50日简单移动均线切入位为0.40美元，200日简单移动均线切入位为0.85美元。木通治疗公司的12个月低点为0.30美元，12个月高位为3.35美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds have recently added to or reduced their stakes in AKBA. Point72 Hong Kong Ltd bought a new position in Akebia Therapeutics during the 4th quarter valued at about $30,000. BNP Paribas Arbitrage SA increased its holdings in Akebia Therapeutics by 123.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $40,000. Finally, MetLife Investment Management LLC grew its holdings in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 54,389 shares in the last quarter. 31.56% of the stock is owned by hedge funds and other institutional investors.
多家对冲基金最近增持或减持了Akba的股份。Point72 Hong Kong Ltd在第四季度购买了木通治疗公司的新头寸，价值约30,000美元。法国巴黎银行套利公司在第二季度增持了木通治疗公司123.7的股份。法国巴黎银行套利公司现在拥有90,540股这家生物制药公司的股票，价值32,000美元，在上个季度额外购买了50,066股。GSA Capital Partners LLP在第一季度购买了Akebia Treeutics的新股份，价值约3.9万美元。Mirabella Financial Services LLP在第一季度购买了Akebia治疗公司的新股份，价值约为4万美元。最后，大都会人寿投资管理有限责任公司在第一季度增持了木通治疗公司的股份176.6%。大都会人寿投资管理有限责任公司现在拥有85,186股这家生物制药公司的股票，价值61,000美元，上个季度又购买了54,389股。31.56%的股票由对冲基金和其他机构投资者持有。
About Akebia Therapeutics
木通治疗公司简介
(Get Rating)
(获取评级)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治疗公司是一家生物制药公司，专注于肾脏疾病患者治疗药物的开发和商业化。该公司的主要研究产品候选产品是vadustat，这是一种口服疗法，正处于第三阶段开发，用于治疗依赖透析和非透析依赖的成年患者的慢性肾脏疾病(CKD)引起的贫血。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- 免费获取StockNews.com关于木通治疗的研究报告(AKBA)
- 对于这三只股票来说，这可能是一个值得记住的9月
- 在预订增加的情况下，Roblox能否扭转预订量下降的局面
- 通胀峰值为布林克国际股票设定底部
- 博通从机构底部反弹
- AutoZone是在收益发布之前买入的吗？
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对木通治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧